-

01:20:34 AM

Latest NVAX Stock Market News

NVAX - Novavax, Inc.

09/16/21 7:02 PM

Nasdaq : NVAX

conferencescovid-19

Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called Comparing

RHEA-AI

neutral

09/09/21 9:25 AM

Nasdaq : NVAX

conferences

Novavax to Participate in Upcoming September Conferences

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based

RHEA-AI

neutral

09/08/21 8:16 AM

Nasdaq : NVAX

clinical trialcovid-19

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the

RHEA-AI

neutral

09/07/21 9:05 AM

Nasdaq : NVAX

conferences

Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi's 16 th Annual BioPharma Virtual Conference 2021 investor conference. Novavax'

RHEA-AI

neutral

08/30/21 4:07 PM

Nasdaq : NVAX

clinical trialcovid-19

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance for those who have

RHEA-AI

neutral

08/25/21 9:27 AM

Nasdaq : NVAX

conferences

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax' recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO, now underway

RHEA-AI

neutral

08/16/21 8:50 AM

Nasdaq : NVAX

management

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and

RHEA-AI

neutral

08/05/21 4:05 PM

Nasdaq : NVAX

earnings

Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2021. "We are highly

RHEA-AI

neutral

08/05/21 4:04 PM

Nasdaq : NVAX

covid-19

Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series Analysis of sera from primary vaccination

RHEA-AI

neutral

08/05/21 4:03 PM

Nasdaq : NVAX

covid-19

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine

- Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax' recombinant nanoparticle COVID-19 vaccine- Filing for World Health Organization Emergency Use Listing expected in August

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

NVAX Data:

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.novavax.com
CeoStanley Erck
Security nameNovavax, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees791
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address21 Firstfield Rd
StateMaryland
CityGaithersburg
Zip20878-1757
CountryUS
Phone12402682000

NVAX Description:

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.